Compare Herbalife Nutrition Ltd (HLF) vs Moderna, Inc. (MRNA) Price & Performance

HLF trades at $12.04, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations of $0.607, and raised full-year guidance. Revenue for 2025 was $5.04 billion with a net income margin of 4.66%, while valuation ratios remain low with a P/E of 5.38 and P/S of 0.25. Recent news includes Herbalife's inclusion in TIME's America's Best Companies 2026 and a $1.45 billion debt refinancing completed in April 2026.

The outlook for HLF is cautiously optimistic due to strong earnings beats and strategic initiatives, but risks include high debt levels and competitive pressures. Analyst consensus is 57.69% buy, with institutional sentiment leaning positive amid ongoing business transformation efforts.

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.